Nordhealth AS (OSL:NORDH)

Norway flag Norway · Delayed Price · Currency is NOK
26.20
0.00 (0.00%)
Jun 3, 2026, 4:25 PM CET
Market Cap2.06B -32.0%
Revenue (ttm)582.01M +8.0%
Net Income-170.74M
EPSn/a
Shares Out 78.81M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145
Open26.40
Previous Close26.20
Day's Range26.20 - 26.40
52-Week Range21.20 - 40.60
Beta0.33
Analystsn/a
Price Targetn/a
Earnings DateMay 12, 2026

About Nordhealth AS

Nordhealth AS provides healthcare software solutions in Norway, Finland, Sweden, the United Kingdom, Denmark, DACH, and internationally. Its products include Provet, a practice management software platform for veterinary clinics and enterprise groups, providing appointment scheduling, patient management, electronic health records, billing and invoicing, reporting and analytics, government compliance tools, communication features, inventory management, and workflow automation; Diarium, a PMS for therapists that streamlines therapy sessions, book... [Read more]

Sector Healthcare
Founded 2001
Employees 457
Stock Exchange Oslo Børs
Ticker Symbol NORDH
Full Company Profile

Financial Performance

In 2025, Nordhealth AS's revenue was 50.84 million, an increase of 11.31% compared to the previous year's 45.68 million. Losses were -12.68 million, 65.2% more than in 2024.

Financial numbers in EUR Financial Statements

News

Nordhealth AS Earnings Call Transcript: Q1 2026

Q1 2026 revenue rose 7.9% year-over-year to EUR 13.5 million, driven by strong recurring revenue and AI product adoption. Veterinary and Therapy segments posted double-digit ARR growth, and 2026 guidance for revenue and EBITDA minus CapEx is reaffirmed.

22 days ago - Transcripts

Nordhealth AS Slides: Q1 2026

Nordhealth AS has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.

22 days ago - Filings

Nordhealth AS Earnings Call Transcript: Q4 2025

Revenue surpassed EUR 50 million in 2025, with strong recurring growth and low churn. AI strategy and cloud migration are driving operational improvements, while profitability is impacted by ongoing R&D and migration costs. Guidance for 2026 targets continued recurring revenue growth and investment in AI.

3 months ago - Transcripts

Nordhealth AS Annual report: Q4 2025

Nordhealth AS has published its Q4 2025 annual report on March 3, 2026.

3 months ago - Filings

Nordhealth AS Slides: Q4 2025

Nordhealth AS has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 3, 2026.

3 months ago - Filings

Nordhealth AS Earnings Call Transcript: Q3 2025

Q3 2025 saw 15.2% revenue growth, driven by strong recurring revenue in core business units and significant R&D investment in AI and DACH localization. Veterinary and Therapy segments posted robust retention and low churn, while guidance for 2025 was reiterated.

7 months ago - Transcripts

Nordhealth AS Slides: Q3 2025

Nordhealth AS has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 11, 2025.

7 months ago - Filings

Nordhealth AS Earnings Call Transcript: Q2 2025

Revenue and recurring revenue grew strongly in H1 2025, with major enterprise rollouts and AI features set to drive future growth. Investments in DACH localization and AI are accelerating, while profitability is impacted short-term by these initiatives.

10 months ago - Transcripts

Nordhealth AS Quarterly report: Q2 2025

Nordhealth AS has published its Q2 2025 quarterly earnings report on August 19, 2025.

10 months ago - Filings

Nordhealth AS Slides: Q2 2025

Nordhealth AS has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 19, 2025.

10 months ago - Filings